Do Different Types of Doctors Follow Depression Patients Differently?
Yes. In a claims analysis of 4,102 adults newly diagnosed with major depressive disorder, patients who got their first antidepressant prescription from a psychiatrist were nearly five times as likely as those prescribed by a primary care provider to receive guideline-concordant follow-up, defined as three or more visits in the first 90 days (odds ratio 4.6, 95% CI 3.9 to 5.4). Only 31% of patients overall met that standard. The study, published in Psychiatric Services in 2010, analyzed medical and prescription claims rather than following patients prospectively.
What the data show:
- Provider differences: Patients whose initial prescription came from a psychiatrist had 4.6 times the odds of guideline-concordant follow-up compared with patients prescribed by primary care providers (95% CI 3.9 to 5.4)
- Guideline gaps: Only 31% of the 4,102 patients received three or more follow-up visits during the first 90 days after the index prescription
- What “guideline-concordant” meant here: Three or more follow-up visits in the 90 days after the first antidepressant prescription
- Primary care shortfall: The authors concluded that routine antidepressant management falls short of guideline recommendations, especially in primary care
- Study design: Medical and prescription claims from adults newly diagnosed with major depressive disorder who initiated antidepressant treatment, analyzed with logistic regression and propensity score matching
- Robustness: Sensitivity analyses tested how the results changed when follow-up visits were identified in different ways
- Mechanism: Follow-up visits are the point at which a prescriber can check response, adjust dose, and catch side effects. This study measured whether those visits happened, not what occurred inside them
Dr. Kumar’s Take
Starting an antidepressant is the beginning of treatment, not the end of it. This analysis says that in ordinary practice, most patients did not get back in front of a prescriber even three times in the first three months, and where that first prescription came from mattered a great deal. A nearly fivefold difference in odds between psychiatrist-initiated and primary care-initiated treatment is not a rounding error, and the confidence interval is tight enough that I take the direction seriously. I read this as a systems finding more than a criticism of individual primary care doctors, who carry most of the depression treatment volume alongside everything else. The important caveat for me is that this is claims data: it counts visits, so it tells me about contact frequency and nothing about the quality of what happened at those visits. Three visits with no symptom measurement is not obviously better care than one good one. Still, if a patient is never seen again after the prescription, no adjustment can happen at all.
Study Snapshot
The researchers analyzed medical and prescription claims from adults newly diagnosed with major depressive disorder who initiated antidepressant treatment. They identified follow-up visits during the first 90 days after the index prescription and created an indicator for receipt of guideline-concordant care, defined as three or more visits. Logistic regression models were used, with propensity score matching applied to compare patients across provider specialties, and sensitivity analyses examined how the results differed when follow-up visits were identified in other ways. The final sample was 4,102 patients.
Results in Real Numbers
Only 31% of the 4,102 patients received guideline-concordant follow-up, meaning three or more visits in the 90 days after their first antidepressant prescription.
Provider specialty tracked strongly with that outcome. Patients who received their initial prescription from a psychiatrist were nearly five times as likely as patients prescribed by a primary care provider to receive guideline-concordant follow-up care, with an odds ratio of 4.6 and a 95% confidence interval of 3.9 to 5.4.
The authors concluded that routine care for antidepressant management falls short of guideline recommendations, especially in primary care.
Who Benefits Most
Anyone about to start an antidepressant has a reason to pay attention to this, because the finding is about the first 90 days after that first prescription. Patients whose prescription originates in primary care are the group the authors singled out as least likely to receive the recommended number of follow-up visits, so they stand to gain the most from a follow-up schedule agreed on at the time of prescribing.
Safety, Limits, and Caveats
This is an analysis of medical and prescription claims, not a randomized trial, so it describes an association between provider specialty and follow-up frequency and cannot establish that the specialty caused the difference. Propensity score matching was applied to account for differences between the patient groups, but claims-based comparisons of this kind carry residual confounding.
The outcome measured is a count of visits, not the content or quality of those visits, and not patient outcomes. Nothing here shows that patients who received three or more visits actually did better. The authors ran sensitivity analyses varying how follow-up visits were identified, which suggests the definition of a visit is itself a judgement call in claims data.
Practical Takeaways
- Guideline-concordant care in this study meant three or more follow-up visits in the first 90 days after starting an antidepressant. Only 31% of patients got that.
- Ask for your follow-up appointments to be booked at the time the prescription is written, rather than waiting to see how things go.
- Know that where the prescription comes from is associated with how closely you are followed: psychiatrist-initiated treatment had 4.6 times the odds of concordant follow-up.
- If your treatment is being managed in primary care, that is where the shortfall was largest, so it is worth being explicit about when you will next be seen.
- Report side effects and lack of response between visits rather than waiting for the next scheduled appointment.
What This Means for Depression Treatment
The gap this study describes is between a modest standard, three visits in three months, and what most patients actually received. That is a health system problem more than a knowledge problem. The finding that provider specialty is so strongly associated with follow-up frequency points toward access to psychiatric care and the structure of primary care visits as the places to intervene.
Because the study counted visits and not outcomes, it establishes where care deviates from guidelines without establishing what that deviation costs patients. That is the next question, and this analysis does not answer it.
Related Studies and Research
Measurement-Based Care: Practical Strategy for Behavioral Health
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
FAQs
How often should I see my doctor after starting an antidepressant?
This study used three or more follow-up visits during the first 90 days after the first prescription as its measure of guideline-concordant care. Only 31% of the patients studied reached it.
Does it matter what type of doctor manages my depression treatment?
It was associated with how closely patients were followed. Those whose initial prescription came from a psychiatrist were nearly five times as likely to receive guideline-concordant follow-up as those prescribed by a primary care provider (odds ratio 4.6, 95% CI 3.9 to 5.4).
What should I do if my doctor isn’t scheduling frequent enough follow-ups?
Ask directly for visits to be scheduled through the first three months of treatment, and report side effects or lack of improvement as they happen rather than waiting.
Bottom Line
In 4,102 adults starting antidepressants, only 31% received three or more follow-up visits in the first 90 days, and patients whose prescription came from a psychiatrist were nearly five times as likely to hit that mark as those treated in primary care.
